Valuation: Tectonic Therapeutic, Inc.

Market Cap 444M 397M 370M 336M 633M 42.95B 638M 4.45B 1.74B 21.84B 1.67B 1.63B 70.22B P/E 2026 *
-4.46x
P/E 2027 * -4.22x
Enterprise Value -30.23M -27.01M -25.2M -22.89M -43.12M -2.92B -43.44M -303M -118M -1.49B -114M -111M -4.78B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
62.4%
Yield 2026 *
-
Yield 2027 * -
1 day+1.34%
1 week-2.49%
Current month-2.49%
1 month-26.15%
3 months-37.84%
6 months-21.80%
Current year+8.87%
1 week 21.71
Extreme 21.71
23.42
1 month 21.71
Extreme 21.71
31
Current year 16.77
Extreme 16.77
39.53
1 year 15.32
Extreme 15.315
39.53
3 years 13.7
Extreme 13.7
61.07
5 years 13.7
Extreme 13.7
61.07
10 years 13.7
Extreme 13.7
61.07
Date Insider Type Main position Quantity % Market Cap. Importance
30/09/26 Sell

Chief Technology Officer

-536 0.0027%
25/09/26 Tax

Chief Technology Officer

-525 0.0027%
25/09/26 Tax

Chief Executive Officer

-1,545 0.0079%
Change 5-day change 1-year change 3-year change Capi.($)
+1.34%-2.49%+52.31% - 444M
+4.16%+4.16%+49.37%+94.17% 74.68B
-13.40%-13.74%+5.65%+55.46% 58.7B
-1.35%+1.21%+4.15%+32.26% 48.36B
+0.50%-2.14%+331.33%+702.20% 43.05B
-0.72%-3.99%+28.50%+29.94% 42.48B
+0.34%-0.52%+6.56%+109.35% 41.39B
-0.11%+1.96%+9.19%+52.66% 31.29B
-0.50%-3.10%-10.19%-14.35% 23.93B
-3.32%-10.86%-37.32%+316.28% 22.22B
Average -1.31%-2.21%+43.95%+153.11% 38.65B
Weighted average by Cap. -1.62%-1.57%+49.68%+145.58%

Financials

2026 *2027 *
Net sales - -
Net income -102M -90.97M -84.87M -77.09M -145M -9.85B -146M -1.02B -398M -5.01B -382M -374M -16.1B -135M -121M -113M -102M -193M -13.06B -194M -1.35B -529M -6.64B -507M -496M -21.36B
Net Debt -474M -424M -395M -359M -676M -45.87B -681M -4.75B -1.86B -23.33B -1.78B -1.74B -75B -343M -306M -286M -260M -489M -33.18B -493M -3.44B -1.34B -16.87B -1.29B -1.26B -54.25B
Projected Income Statement - Annual - Tectonic Therapeutic, Inc.
Logo Tectonic Therapeutic, Inc.
Tectonic Therapeutic, Inc. is a clinical-stage biotechnology company. The Company is focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs). Its technology platform called GEODe (GPCRs Engineered for Optimal Discovery), is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery and harness the human body to modify the course of disease. Its product candidates are TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone relaxin. Its second development candidate, TX2100, is a VHH-Fc fusion antagonist antibody that binds to the APJ receptor (APLNR), also known as the apelin receptor. Its APJ is a differentiated approach for the treatment of hereditary hemorrhagic telangiectasia (HHT) and is a selective anti-angiogenic target that is primarily expressed in endothelial cells.
Employees
60
Date Price Change Volume
07/10/26 US$22.71 +1.34% 300,790
06/10/26 US$22.41 -3.03% 200,936
05/10/26 US$23.11 +2.53% 312,645
02/10/26 US$22.54 -0.57% 253,433
01/10/26 US$22.67 -2.66% 343,507
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Ratings Surperformance© - Tectonic Therapeutic, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
22.71USD
Average target price
76.62USD
Spread / Average Target
+237.41%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Tectonic Therapeutic, Inc.
  1. Stock Market
  2. Stocks
  3. TECX Stock